Premium
Leptin and prostate cancer
Author(s) -
Chang Shine,
Hursting Stephen D.,
Contois John H.,
Strom Sara S.,
Yamamura Yuko,
Babaian Richard J.,
Troncoso Patricia,
Scardino Peter T.,
Wheeler Thomas M.,
Amos Christopher I.,
Spitz Margaret R.
Publication year - 2001
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/1097-0045(200101)46:1<62::aid-pros1009>3.0.co;2-v
Subject(s) - leptin , prostate cancer , medicine , odds ratio , body mass index , prostatectomy , obesity , testosterone (patch) , prostate , confidence interval , endocrinology , cancer , oncology
Background Higher prostate cancer mortality rates among US immigrants from countries with lower rates suggest environmental influences on prostate carcinogenesis (e.g., diet, body composition). Methods In a study identifying determinants of clinically relevant prostate cancer, we compared plasma concentrations of leptin, an adiposity‐related hormone, in 48 men with tumors ≤ 0.5 cc measured after radical prostatectomy and 151 men with tumors > 0.5 cc in volume or with histologic evidence of extraprostatic extension but without metastases (“high‐volume disease”), matched by age (± 5 years) and year at diagnosis (± 1 year). Results Men with high‐volume disease exhibited higher leptin concentrations overall and after stratification by age, testosterone level, height, and body mass index (BMI). Analysis revealed that men with elevated leptin concentrations had an increased risk of diagnosis with high‐volume disease (odds ratio (OR) = 2.35, 95% confidence interval (CI) = 1.01–5.44), as did men with high leptin and high testosterone (OR = 9.73, 95% CI = 2.05–46.24) and men ≥5′8″ with high leptin (OR = 3.67, 95% CI = 1.40–9.63). Conclusions Leptin may affect the risk of clinically relevant prostate cancer through testosterone and factors related to stature and obesity. Prostate 46:62–67, 2001. © 2001 Wiley‐Liss, Inc.